Dan Burgess, Chairman and Chief Executive Officer
Dan Burgess is Chairman and CEO of Pulmocide. Mr. Burgess was previously founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company (now Novartis). Two antibiotics developed by Rempex have since been approved by the FDA. Prior to Rempex he was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis (now Abbvie). The product was ultimately approved in Europe and Canada. Mr. Burgess is also a Venture Partner with SV Health Investors and is chairman of the board of several public and private biotechnology companies.
Dan is a graduate of Stanford University (AB, Economics) and Harvard Business School (MBA).
Dr Lance Berman, Chief Medical Officer
Lance Berman is Chief Medical Officer of Pulmocide and brings over 25 years of experience in clinical development, medical affairs and corporate leadership from his time in big pharma and in the small biotech start-up space. Most recently Lance was Chief Medical Officer and Senior Vice President at Relypsa in the San Francisco Bay area where he was responsible for building and leading the Company’s clinical development, medical affairs and drug safety functions; as well as playing a key role in the preparation and execution of the Company’s IPO. In addition to having worked across multiple therapeutic areas in clinical development, he has also worked closely with commercial teams to secure product reimbursement and to plan and execute product launches. Lance also serves as a Venture Partner at Ysios Capital and sits on the Board of Oxthera.
Lance received his Bachelor of Medicine and Bachelor of Surgery (MB.ChB) degree from the University of Cape Town, South Africa and holds a Master’s in Science in Pharmaceutical Medicine.
Dr Anne Brindley, Managing Director, UK and Head of CMC
Anne Brindley has a dual role in Pulmocide as Managing Director, UK and Head of CMC (Chemistry, Manufacturing and Controls) and she brings over 30 years of experience in pharmaceutical development and corporate leadership from both the big pharma and biotech sectors. Anne was previously CEO of Nuformix plc, whose lead asset was an inhaled therapy for Idiopathic Pulmonary Fibrosis and prior to that, CEO of Advent Pharmaceuticals Pty Ltd, in Australia. Advent developed inhaled generics for the US market, and Anne secured the sale of the company to Aurobindo Pharmaceuticals Inc. Previously Anne was Managing Director and Head of CMC at Respivert (a subsidiary of J&J), that developed a portfolio of novel inhaled compounds for asthma and COPD. Previous roles were at SkyePharma (Switzerland) where she played a key role in achieving European approval of Flutiform(r) inhaler, AstraZeneca (UK and Sweden), with a pivotal role in the US approval of Symbicort(r) inhaler and GlaxoWellcome, where she started her career in the development of inhaled products.
Anne has a Pharmacy degree from the University of Bath and a Ph.D. in drug delivery from the University of Nottingham.
Dr Pete Strong, Chief Scientific Officer and Co-founder
Pete is Pulmocide’s Chief Scientific Officer. Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-founded Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company. With Garth and colleagues, Pete then co-founded Pulmocide Ltd. in 2013.
Jennifer Giottonini Cayer, Chief Business Officer
Ms. Cayer has over twenty-five years of biotech, pharmaceutical and medical device experience. She has co-founded several biotech companies that were funded by blue chip venture investors, acquired by global pharmaceutical companies, or became publicly traded companies. She has executed multiple alliances with pharmaceutical and biotech companies worth over $5B including mergers and acquisitions, drug licensing, technology licensing, drug discovery and development collaborations, and company spinouts. She is a board member of multiple biotech companies and academic research institutes including Matrisys Biosciences, Devacell, University of California, San Diego Cancer Center, and the Biocom Board of Governors. Ms. Cayer is the Founding Chair of the Biocom Global Partnering Conference and a member of Corporate Directors Forum.
Ms. Cayer graduated from University of California, San Diego with a BS in Bioengineering.
Dr David Mantus, President, US Operations
David Mantus, Ph.D. is President, US Operations at Pulmocide. Prior to joining Pulmocide he was Chief Development Officer, and Managing Director, Arsanis Biosciences GmbH, at Arsanis, Inc. He has more than 28 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. Dr. Mantus has led teams responsible for all aspects of product development, from pre-IND through global commercialization and partnering. Prior to Arsanis he held leadership roles in development at Seres Health, Cubist Pharmaceuticals, Shire Biologics, and Procter & Gamble Pharmaceuticals.
Dr. Mantus received his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington.
Joe Suarez, Acting Chief Financial Officer
Joe Suarez is the acting Chief Financial Officer of Pulmocide and brings nearly 30 years of progressive financial experience across life science companies. Joe has demonstrated experience in strategic planning, mergers, acquisitions, private placements, financial reporting, accounting, budgeting, and financial planning and analysis. Between 2005 and 2018, Joe held various roles of increasing responsibility at Arisaph Pharmaceuticals, culminating in his service as Chief Business Officer and a member of the executive team. During his tenure at Arisaph, he led corporate finance and business development initiatives resulting in approximately $90 million of non-dilutive income.
Joe received his Bachelor of Science degree in Accounting from George Mason University and his Master’s in Business Administration from the University of Maryland.